Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr18.50
-kr0.25(-1.52%)
At close: 4:00 PM EDT
kr18.50
-kr0.25(-1.52%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr38.43
Previous CloseN/A
Volume661.00
Average Volume (3M)5.64K
Market Cap
kr328.76M
Enterprise Valuekr147.98
Total Cash (Recent Filing)kr186.77M
Total Debt (Recent Filing)kr11.68M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume8,003
30 Day Avg. Volume5,640
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelThe consumables model can create repeat revenue from each installed instrument as testing volumes develop, providing a more scalable foundation than relying only on one-time analyzer sales. Growing recurring usage could improve revenue visibility and support operating leverage over time.
Low Current LeverageVery low leverage limits direct borrowing-related financial risk and preserves greater flexibility to allocate resources toward commercialization, product development, or operations. Positive equity currently provides some balance-sheet support despite the company’s ongoing losses and cash consumption.
Clinically Relevant Rapid Diagnostics PlatformA platform that helps clinicians identify effective antibiotics more quickly addresses an important clinical need in hospital laboratories. The combination of instruments, cartridges, and software can support a focused diagnostic franchise if adoption expands across relevant care settings.
Bears Say
Persistent Unprofitable OperationsDeep losses across gross, operating, and net levels indicate that the current business has not yet reached a viable cost structure. Continued unprofitability can consume equity, constrain investment capacity, and make durable earnings improvement dependent on substantial operating progress.
Heavy Cash BurnMaterially negative operating and free cash flow means operations continue to require significant funding rather than self-financing growth. Persistent burn reduces financial resilience and may force difficult capital allocation decisions before the installed base generates sufficient recurring cash.
Modest And Volatile Revenue BaseA modest revenue base with limited recent growth provides little evidence yet of broad commercial scale or strong operating leverage. Revenue volatility also makes it harder to absorb the company’s fixed cost base and increases the execution burden for expanding platform adoption.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr38.42 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr328.76M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Oct 30, 2026 which is in 27 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Jul 10, 2026. The company reported -kr1.58 earnings per share for the quarter.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.58 in its last earnings report. Following the earnings report the stock price went up 7.453%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.